drugset
drugset / Trial / NCT00483860

A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function

NCT00483860 ↗

Phase 1 Completed 59 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the effect of renal impairment and prior platinum-based chemotherapy on the safety and blood levels of topotecan administered orally

Timeline

Start
2007-06-20
Primary completion
2012-02-06
Completion
2012-02-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Topotecan Small molecule — Oral

Indications

cancer